MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns ... and ...

Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration ... was easily removed with debridement scissors (see Figure ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... in Phase III development for the debridement of chronic wounds.

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... in Phase III development for the debridement of chronic wounds.

Faster eschar removal: NexoBrid achieved complete ... a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx ...

MediWound's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness ... candidate currently in Phase III development for the debridement of ...